Compare FNWB & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | PYPD |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.7M | 85.1M |
| IPO Year | 2012 | 2014 |
| Metric | FNWB | PYPD |
|---|---|---|
| Price | $10.05 | $4.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.50 | $12.25 |
| AVG Volume (30 Days) | 25.4K | ★ 116.2K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $2.79 |
| 52 Week High | $10.98 | $5.20 |
| Indicator | FNWB | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 59.43 |
| Support Level | $9.18 | $4.15 |
| Resistance Level | $10.34 | $5.05 |
| Average True Range (ATR) | 0.29 | 0.27 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 82.57 | 70.59 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.